In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-b4 as markers of malignant intraductal pancreatic mucinous neoplasms

Pancreatology

Volumn 14, Issue 2, 2014, Pages 117-124

  Rebours, Vinciane ^a,b   Le Faouder, Julie ^b   Laouiremb, Samira ^b   Mebarki, Mounya ^b   Albuquerque, Miguel ^a,b   Camadro, Jean Michel ^c   Léger, Thibaut ^c   Ruszniewski, Philippe ^a,b   Lévy, Philippe ^a   Paradis, Valérie ^a,b   Bedossa, Pierre ^a,b   Couvelard, Anne ^b,d  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c INSTITUT JACQUES MONOD   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

Biomarker hunting; Imaging mass spectrometry; IPMN; MALDI; Pancreatic precancerous lesions; Proteomics; Thymosin b4; Ubiquitin

Indexed keywords

BIOLOGICAL MARKER; THYMOSIN BETA4; UBIQUITIN;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSPLASIA; ELECTROSPRAY MASS SPECTROMETRY; ENDOSCOPIC ECHOGRAPHY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PANCREAS RESECTION; PARTICLE SIZE; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SAMPLE; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TISSUE SECTION;

BIOMARKER HUNTING; IMAGING MASS SPECTROMETRY; IPMN; MALDI; PANCREATIC PRECANCEROUS LESIONS; PROTEOMICS; THYMOSIN-Β4; UBIQUITIN;

AGED; AMINO ACID SEQUENCE; FEMALE; HUMANS; HYDROLYSIS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; PROTEOMICS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THYMOSIN; TRYPSIN; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN;

EID: 84900484113     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2013.12.001     Document Type: Article

References (35)

1. Itai Y, Ohhashi K, Nagai H, Murakami Y, Kokubo T, Makita K, et al. "Ductectatic" mucinous cystadenoma and cystadenocarcinoma of the pancreas. Radiology 1986;161(3):697e700.
2. Klöppel G, Solcia E, Capella C, Sobin IH. International histological typing of tumors of the exocrine pancreas; 1996.
3. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004;28(8):977e87.
4. Shi C, Klein AP, Goggins M, Maitra A, Canto M, Ali S, et al. Increased prevalence of precursor lesions in Familial pancreatic cancer patients. Clin Cancer Res 2009;15(24):7737e43.
5. Levy P, Jouannaud V, O'Toole D, Couvelard A, Vullierme MP, Palazzo L, et al. Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol 2006;4(4):460e8.
6. Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al., International Association of Pancreatology. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012 MayeJun;12(3):183e97.
7. Corcos O, Couvelard A, Dargere D, Sauvanet A, Hammel P, Paradis V, et al. Proteomic assessment of markers for malignancy in the mucus of intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2012;41(2):169e74.
8. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001;7(4):493e6.
9. Fournier I, Day R, Salzet M. Direct analysis of neuropeptides by in situ MALDITOF mass spectrometry in the rat brain. Neuro Endocrinol Lett 2003;24(1e2): 9e14.
10. Kang MJ, Jang JY, Kim SJ, Lee KB, Ryu JK, Kim YT, et al. Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms. Clin Gastroenterol Hepatol 2011;9(1):87e93.
11. Rautou PE, Levy P, Vullierme MP, O'Toole D, Couvelard A, Cazals-Hatem D, et al. Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol 2008;6(7):807e14.
12. Nagai K, Doi R, Ito T, Kida A, Koizumi M, Masui T, et al. Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg 2009;16(3):353e8.
13. Sai JK, Suyama M, Kubokawa Y, Watanabe S, Maehara T. Pancreatic- ductlavage cytology in candidates for surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas: should the International Consensus Guidelines be revised? Gastrointest Endosc 2009;69(3 Pt 1):434e 40.
14. Sadakari Y, Ienaga J, Kobayashi K, Miyasaka Y, Takahata S, Nakamura M, et al. Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules. Pancreas 2010;39(2):232e6.
15. Kim SC, Park KT, Lee YJ, Lee SS, Seo DW, Lee SK, et al. Intraductal papillary mucinous neoplasm of the pancreas: clinical characteristics and treatment outcomes of 118 consecutive patients from a single center. J Hepatobiliary Pancreat Surg 2008;15(2):183e8.
16. Kawamoto S, Lawler LP, Horton KM, Eng J, Hruban RH, Fishman EK. MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma. AJR Am J Roentgenol 2006;186(3): 687e95.
17. Maire F, Voitot H, Aubert A, Palazzo L, O'Toole D, Couvelard A, et al. Intraductal papillary mucinous neoplasms of the pancreas: performance of pancreatic fluid analysis for positive diagnosis and the prediction of malignancy. Am J Gastroenterol 2008;103(11):2871e7.
18. Yamaguchi K, Nakamura M, Shirahane K, Kawamoto M, Konomi H, Ohta M, et al. Pancreatic juice cytology in IPMN of the pancreas. Pancreatology 2005;5(4e5):416e21.
19. Khalid A, McGrath KM, Zahid M, Wilson M, Brody D, Swalsky P, et al. The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 2005;3(10):967e73.
20. Khalid A, Zahid M, Finkelstein SD, LeBlanc JK, Kaushik N, Ahmad N, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc 2009;69(6):1095e102.
21. Ryu JK, Matthaei H, Dal Molin M, Hong SM, Canto MI, Schulick RD, et al. Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology 2011;11(3):343e50.
22. Clague MJ, Urbe S. Ubiquitin: same molecule, different degradation pathways. Cell 2010;143(5):682e5.
23. Ni XG, Zhou L, Wang GQ, Liu SM, Bai XF, Liu F, et al. The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer. Mol Med 2008;14(9e10):582e9.
24. Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, et al. Wholeexome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 2011;108(52):21188e93.
25. Hertzog M, van Heijenoort C, Didry D, Gaudier M, Coutant J, Gigant B, et al. The beta-thymosin/WH2 domain; structural basis for the switch from inhibition to promotion of actin assembly. Cell 2004;117(5):611e23.
26. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005;11(9): 421e9.
27. Young JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, et al. Thymosin beta 4 sulfoxide is an anti-inflammatory agents generated by monocytes in the presence of glucocorticoids. Nat Med 1999;5(12):1424e7.
28. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res 2002;74(2):293e9.
29. Hardesty WM, Kelley MC, Mi D, Low RL, Caprioli RM. Protein signatures for survival and recurrence in metastatic melanoma. J Proteomics 2011;74(7): 1002e14.
30. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003;22(39):8031e41.
31. Nummela P, Yin M, Kielosto M, Leaner V, Birrer MJ, Holtta E. Thymosin beta4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblasts. Cancer Res 2006;66(2):701e12.
32. Liu CR, Ma CS, Ning JY, You JF, Liao SL, Zheng J. Differential thymosin beta 10 expression levels and actin filament organization in tumor cell lines with different metastatic potential. Chin Med J (Engl) 2004;117(2):213e8.
33. Nemolato S, Cabras T, Cau F, Fanari MU, Fanni D, Manconi B, et al. Different thymosin Beta 4 immunoreactivity in foetal and adult gastrointestinal tract. PLoS One 2010;5(2):e9111.
34. Zhang Y, Feurino LW, Zhai Q, Wang H, Fisher WE, Chen C, et al. Thymosin Beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation. Cancer Biol Ther 2008;7(3):419e23.
35. Grüner BM, Hahne H, Mazur PK, Trajkovic-Arsic M, Maier S, Esposito I, et al. MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer. PLoS One 2012;7(6):e39424.